计算溶液所需的质量、体积或浓度。
Namilumab (anti-GM-CSF) (Ab175608) - ELISA
Immobilized Recombinant Human GM-CSF Protein (rp156011) at 1.0 μg/mL can bind Namilumab (anti-GM-CSF) (Ab175608) with the EC50 of 62.67 ng/mL.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| Ab175608-100μg |
100μg |
现货 ![]() |
| |
| Ab175608-1mg |
1mg |
现货 ![]() |
| |
| Ab175608-5mg |
5mg |
现货 ![]() |
| |
| Ab175608-10mg |
10mg |
期货 ![]() |
|
| 产品名称 | Namilumab (anti-GM-CSF), 粒细胞-巨噬细胞集落刺激因子抑制剂 |
|---|---|
| 别名 | 那美芦单抗 | 纳米单抗(抗 GM-CSF) |
| 英文别名 | Colony stimulating factor 2 (granulocyte-macrophage) antibody | Colony Stimulating Factor 2 antibody | Colony stimulating factor antibody | Colony-stimulating factor antibody | CSF 2 antibody | CSF antibody | CSF2 antibody | CSF2_HUMAN antibody | GM-CSF a |
| 规格或纯度 | 无载体, 重组, ExactAb™, 低内毒素, 无叠氮钠, 已验证, 无动物源, ≥95%(SDS-PAGE&SEC-HPLC), 见COA |
| 宿主种属 | 人(Human) |
| 特异性 | CSF2 |
| 种属反应性 | 人(Human),恒河猴(Rhesus monkey),食蟹猴(Cynomolgus monkey) |
| 偶联 | Unconjugated |
| 作用类型 | 抑制剂 |
| 作用机制 | 粒细胞-巨噬细胞集落刺激因子抑制剂 |
| 克隆类型 | 重组抗体 |
|---|---|
| Format | Whole IgG |
| 亚型 | Human IgG1 |
| 轻链亚型 | kappa |
| SDS-PAGE | 26.3 kDa (Light Chain) & 51.1 kDa (Heavy Chain), under reducing conditions; 190.1 kDa, under non-reducing conditions. |
| 纯化方法 | Protein A purified |
| 物理外观 | Liquid |
| 储存缓冲液 | Supplied as a 0.22μm filtered solution in 100mM Pro-Ac, 20mM Arg, pH 5.0 |
| 防腐剂 | No |
| 浓度 | 见COA |
| 储存温度 | -80℃储存,避免反复冻融 |
| 运输条件 | 超低温冰袋运输 |
| 稳定性与储存 | Store at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle. |
| CAS编号和信息 | 1206681-39-1 |
| 分子类型 | 抗体 |
Namilumab (anti-GM-CSF) (Ab175608) - ELISA
Immobilized Recombinant Human GM-CSF Protein (rp156011) at 1.0 μg/mL can bind Namilumab (anti-GM-CSF) (Ab175608) with the EC50 of 62.67 ng/mL.
Namilumab (anti-GM-CSF) (Ab175608) - SEC
The purity of Namilumab (anti-GM-CSF) (Ab175608) is more than 95% verified by HPLC.
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
通过匹配包装上的批号来查找并下载产品的 COA,每批产品都进行了严格的验证,您可放心使用!
| 批号(Lot Number) | 证书类型 | 日期 | 货号 |
|---|---|---|---|
| 分析证书 | 24-06-21 | Ab175608 | |
| 分析证书 | 24-06-21 | Ab175608 | |
| 分析证书 | 24-06-21 | Ab175608 |
¥669.90
¥669.90
¥479.90
¥669.90
¥469.90
| 1. Plater-Zyberk C, Joosten LA, Helsen MM, Hepp J, Baeuerle PA, van den Berg WB. (2007) GM-CSF neutralisation suppresses inflammation and protects cartilage in acute streptococcal cell wall arthritis of mice.. Ann Rheum Dis, 66 (4): (452-7). [PMID:17020908] |
| 2. Krinner EM, Raum T, Petsch S, Bruckmaier S, Schuster I, Petersen L, Cierpka R, Abebe D, Mølhøj M, Wolf A et al.. (2007) A human monoclonal IgG1 potently neutralizing the pro-inflammatory cytokine GM-CSF.. Mol Immunol, 44 (5): (916-25). [PMID:16697465] |
| 3. Huizinga TW, Batalov A, Stoilov R, Lloyd E, Wagner T, Saurigny D, Souberbielle B, Esfandiari E. (2017) Phase 1b randomized, double-blind study of namilumab, an anti-granulocyte macrophage colony-stimulating factor monoclonal antibody, in mild-to-moderate rheumatoid arthritis.. Arthritis Res Ther, 19 (1): (53). [PMID:28274253] |
| 4. Papp KA, Gooderham M, Jenkins R, Vender R, Szepietowski JC, Wagner T, Hunt B, Souberbielle B, NEPTUNE investigators. (2019) Granulocyte-macrophage colony-stimulating factor (GM-CSF) as a therapeutic target in psoriasis: randomized, controlled investigation using namilumab, a specific human anti-GM-CSF monoclonal antibody.. Br J Dermatol, 180 (6): (1352-1360). [PMID:30207587] |
| 5. Taylor PC, Saurigny D, Vencovsky J, Takeuchi T, Nakamura T, Matsievskaia G, Hunt B, Wagner T, Souberbielle B, NEXUS Study Group. (2019) Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: a randomized, controlled trial.. Arthritis Res Ther, 21 (1): (101). [PMID:30999929] |